Cancer Prevention Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has filed for an initial public offering of its common stock. The Tucson, Arizona-based company is offering 1.92 million of its shares in the IPO at an expected price range of $12 to $14, to raise $25 million. The sole bookrunner for the offering is Aegis Capital Corp.